-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 19th, Tianyan Pharmaceutical (NASDAQ: ADAG) announced that it had reached a third clinical trial cooperation agreement with Merck & Co.
The two parties will initiate an open-label, dose escalation and extended study clinical trial (ADG106-P2001/KEYNOTE- D12) to evaluate the clinical efficacy of the combination in patients with advanced or metastatic solid and/or hematological malignancies
(The original text has been deleted)